Hyderabad, April 15 -- : Aurobindo Pharma on Wednesday announced that its subsidiary, TheraNym Biologics Private Limited, has executed an additional product schedule with Merck Sharp & Dohme Singapore Trading Pte Ltd (MSD), expanding their existing contract manufacturing organisation (CMO) agreement.
The development follows the earlier arrangement between the companies announced in May 2024 and further strengthens their ongoing partnership, the Hyderabad-based pharmaceutical major said.
Under the newly signed product schedule, TheraNym Biologics will set up a greenfield project to establish a large-scale mammalian drug substance manufacturing facility, referred to as "Unit 2."The facility will have a total bioreactor capacity of 60 KL, ai...